Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
Innerscope Research sensor vest tests biometric response to visual aids
Rodney Brown on NECN: Hacking into medical devices
Boston Scientific Corp.’s stock tumbled 16 percent in early trading Tuesday after the company lowered its full-year guidance due to weaker-than-expected sales growth in the third quarter.
The Natick-based medical-device maker said net sales will be between $8.13 billion and $8.23 billion for the year, down from an initial projection of $8.1 billion to $8.4 billion.
Net sales for the company during the third quarter of 2009 were $2.03 billion, up three percent from $1.98 billion during the same period last year.
The company posted a $200 million profit for the quarter ended Sept. 30, versus a loss of $62 million for the corresponding period in 2008. Net income for the first nine months of the year was $345 million, down from $358 for the first three quarters of 2008.
As of Sept. 30, Boston Scientific had $1.38 billion in cash on hand, down from $1.64 billion at the same point last year.
Company officials said the company pre-paid $225 million in term-loan debt during the quarter. Boston Scientific also settled litigation with Johnson & Johnson over intellectual property rights tied to Boston Scientific’s cardiac stents, a move that cost the company $716 million.
Boston Scientific’s (NYSE: BSX) stock was priced around $8.48 a share in morning trading Tuesday, down from the previous-day’s close of $10.16 a share.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
